Cruz GLM, Rodríguez GJH, Monares ZE, Galindo MCA, Pérez GBS, Aportela VVA

Language: Spanish
References: 9
Page: 78-83
PDF size: 254.29 Kb.

ABSTRACT

Introduction: The three domains of glycemic control (hypoglycemia, hyperglycemia and glycemic variability) comprise a conceptual framework for reducing the risk associated with it during critical illness. However, the premorbid component is usually not taken into account. It has been shown that those patients with chronic hyperglycemia could benefit from more liberal glycemic goals, contrary to what has been shown in patients with good premorbid glycemic control.
Material and methods: By using the glycosylated hemoglobin (HbA1c) and predicted glucose of the previous 90 days, a formula of «relative glycemic variability» (RGV) in critically ill adult patients was developed. Then, using the capillary glucose values, events of hypoglycemia were obtained, as well as mean capillary glucose, RGV and coefficient of variation (CV) during the first seven days of stay. The population was divided into HbA1c ‹ 7% and ≥ 7%, as well as in alive and deceased; the variables between them captured and calculated were compared.
Results: Using the glycemic control protocol, HbA1c ≥ 7% patients maintained a negative RGV, that is, lower values than usual; the group ‹ 7% kept a positive RV, higher than usual. The first group showed a prolonged hospital stay, nine versus seven days (p ‹ 0.05), and those deceased and with HbA1c ‹ 7% showed a higher CV (p ‹ 0.05), 27.49 (11.02-37.07) versus 12.49 (8.2-8.75); such association was not observed in the group of patients ≥ 7%.
Conclusion: Negative RGV in relation to premorbid control shows negative effects on the evolution of patients with poor previous glycemic control; at the same time, a greater CV showed its negative effect in patients with good previous control. It is reasserted that, in relation to glycemic control, «one size does not fit all».

REFERENCES

1. Honiden S, Inzcchi SE. Metabolic management during critical illness: glycemic control in the ICU. Semin Respir Crit Care Med. 2015;36:859-869.

2. Van Hooijdonk RT, Mesotten D, Krinsley JS, Schultz MJ. Sweet spot: glucose control in the intensive care unit. Semin Respir Crit Care Med. 2016;37:57-67.

3. Clain J, Ramar K, Surani SR. Glucose control in critical care. World J Diabetes. 2015;6(9):1082-1091.

4. Krinsley JS. Glycemic control in the critically ill: what have we learned since nice-sugar? Hosp Pract (1995). 2015; 43(3): 191-197.

5. Meyfroidt G. Blood glucose amplitude variability in critically ill patients. Minerva Anestesiol. 2015;81:1010-1018.

6. Baithwaite SS. Glycemic variability in hospitalized patients choosing metrics while awaiting evidence. Curr Diab Rep. 2013;13:138-154.

7. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-1478.

8. Donati A, Damiani E, Domizi R, Botticelli L, Castagnani R, Gabbanelli V, et al. Glycaemic variability, infections and mortality in a medical-surgical intensive care unit. Crit Care Resusc. 2014;16:13-23.

9. Krinsley JS, Egi M, Kiss A, Devendra AN, Schuetz P, Maurer PM, et al. Diabetic status and the relation of the three domains of glycemic control to mortality in critically ill patients: an international multicenter cohort study. Critical Care. 2013;17:R37.